Immunotherapy and prostate cancer

Joseph M. Kaminski, James B. Summers, Matthew B. Ward, Mark R. Huber, Boris Minev

Research output: Contribution to journalReview article

28 Scopus citations

Abstract

Prostate cancer is the second leading cause of cancer death in the US, largely because of the limitations of our current therapeutic options, especially once the cancer has metastasized. Investigators have long sought new therapeutic modalities such as angiogenesis inhibitors, vaccines, and gene therapy, among others. It appear's that a combination approach will be required to cure the majority of malignancies. Immunotherapy for prostate cancer appears feasible and a likely therapeutic modality in the armamentarium. Unfortunately, further research in basic immunology and the interaction of the immune system with other forms of therapy is needed. Many obstacles exist in immunotherapy, including vector design, tumouricidal specificity, and tumor evasion, which will have to be overcome in order to realize the maximum therapeutic benefit from this treatment modality.

Original languageEnglish (US)
Pages (from-to)199-209
Number of pages11
JournalCancer Treatment Reviews
Volume29
Issue number3
DOIs
StatePublished - Jun 2003

    Fingerprint

Keywords

  • Cancer
  • Gene therapy
  • Immunotherapy
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Kaminski, J. M., Summers, J. B., Ward, M. B., Huber, M. R., & Minev, B. (2003). Immunotherapy and prostate cancer. Cancer Treatment Reviews, 29(3), 199-209. https://doi.org/10.1016/S0305-7372(03)00005-7